According to the original agreement, Scribe received $15 million upfront from Biogen with an additional $400 million in potential development and commercial milestone payments. The therapy is an expansion of the duo's original agreement signed in October of 2020, to develop CRISPR-based genetic medicines that will address the underlying cause of ALS. In 2014, Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology.Scribe Therapeutics and Biogen are taking their collaboration up a notch, adding another disease target in the study of a treatment for amyotrophic lateral sclerosis disease (ALS). Intellia intends to advance its pipeline and potentially develop a new drug class by leveraging its leading scientific and clinical development expertise and its exclusive access to one of the most comprehensive intellectual property platforms available. Intellia Therapeutics USA Listed Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. This robust set of industry-leading tools lays the foundation for developing a safer, more durable, and more efficient suite of treatments. Poseida’s vision is to create best-in-class gene engineering technologies – spanning gene insertion, gene editing, and delivery. Poseida Therapeutics USA Listed Poseida Therapeutics is a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create ground-breaking, life-saving cell and gene therapies for patients with high unmet medical need. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. Headquartered in Silicon Valley, Synthego is used by scientists from the largest global biotechnology companies and global biology universities to unlock the potential of gene editing.Ĭrispr Therapeutics Switzerland Listed CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company's automated, full-stack genome engineering platform enables broader access to CRISPR to accelerate basic scientific discovery, uncover critical disease cures and develop novel synthetic biology applications to solve some of society's biggest challenges. Synthego USA Private Synthego is the genome engineering innovation company. We intend to continue developing therapeutics using our proprietary platform, active CRISPR proteins, such as Cas9, and the target-specific guide RNA (and DNA template molecules when required). The Incisive Delivery System™ is a proprietary, non viral delivery method for CRISPR based gene therapies. There is a unique opportunity in the gene therapy space for development of a superior platform delivery technology. We believe the proprietary Incisive Delivery System™ provides a solution to the most critical challenge to effective CRISPR-based gene therapy - the effective and safe delivery of active gene editing machinery into in vivo target tissues. (IG) is a Canadian biotech firm that is focused on developing its innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. Incisive Genetics Canada Private Incisive Genetics Inc. Using these two nucleases, we can access a broad range of genetic mutations and develop targeted and durable CRISPR medicines. Both nucleases have distinct gene editing and targeting capabilities. Editas Medicine works with 2 distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). We have focused our research and development efforts on diseases for which there are currently few or no treatments available. VentureRadar Research / Company WebsiteĪssociated sectors: Life Sciences Biopharmaceutical CRISPR platform Biotech CRISPR Gene Therapy Website archive shows the site was first archived on 2004.Įditas Medicine USA Listed Our mission is to translate the power and potential of CRISPR gene editing into a broad class of medicines that can transform lives. X-editing (XE) technology is our first engineered molecule built holistically on a novel CRISPR foundation to provide three key attributes needed for therapeutic use and in vivo genetic modification: greater activity, specificity and deliverability. We are rapidly generating hundreds of synthetic CRISPR molecules and novel technologies every month and folding the best into a fully integrated set of genome editing modalities. Scribe is building and applying a suite of CRISPR technologies into a single continually evolving and expanding genetic modification platform.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |